For decades, patients battling T-cell acute lymphoblastic leukemia (T-ALL) and its close relative, peripheral T-cell lymphoblastic lymphoma (PTCL), have faced a stark reality: a significant void in targeted therapeutic options. Their treatment landscape has been largely confined to aggressive combination chemotherapy regimens. While these protocols offer initial hope, a sobering statistic emerges: approximately 60% of patients treated with first-line chemotherapy will unfortunately experience disease progression, leading to refractory or relapsed (R/R) conditions that necessitate the complex and often challenging procedure of hematopoietic stem cell transplantation (HCT).
The advent of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL), transforming outcomes for countless patients. However, this groundbreaking success has not yet translated to T-cell lymphomas and leukemias. The primary impediment has been a phenomenon known as "fratricide." In essence, the very antigens that mark malignant T-cells for destruction are also present on the surface of the therapeutic CAR-T cells themselves. This molecular overlap leads to the unintended self-elimination of the engineered immune cells, rendering them ineffective against the targeted cancer. This inherent challenge has underscored the urgent need for innovative approaches to overcome fratricide and unlock the therapeutic potential of CAR-T technology for T-cell malignancies.
Navigating the Fratricide Hurdle: A Novel Nanobody Approach
A pivotal moment in this pursuit of effective T-cell therapies was the presentation of Phase I results from the CONQUER trial at the prestigious American Society for Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2, 2026. Researchers from Peking University People’s Hospital unveiled findings for a novel, nanobody-based autologous CD5 CAR-T therapy, specifically designed to address the complexities of T-ALL, PTCL, and cutaneous T-cell lymphoma (TCL).
The target of this innovative therapy, CD5, is a pan-T-cell marker known for its role in regulating T-cell activation. Crucially, it is also highly expressed on the surface of malignant T-cells in these aggressive blood cancers. The CAR-T construct developed, designated SL105, employs a sophisticated mechanism to circumvent the fratricide problem. It leverages the endogenous production of nanobodies within the CAR-T cells. These nanobodies are engineered to bind to and effectively "block" CD5 internally before it can be expressed on the CAR-T cell’s outer membrane. Consequently, any CD5 nanobodies present on the surface of the therapeutic cells are exclusively directed towards recognizing and binding to the target malignant T-cells, thereby eliminating the risk of self-destruction. This elegant solution represents a significant stride in overcoming a long-standing barrier in T-cell CAR-T therapy development.
Early Phase I Trial: Promising Efficacy Amidst Significant Toxicities
The CONQUER trial enrolled 22 adult patients with R/R T-ALL/PTCL and cutaneous TCL. These individuals received a single infusion of SL105, with doses administered at three escalating levels: 0.5, 1.0, or 2.0 x 10^6 CAR-T cells/kg, with a minimum of five patients evaluated at each dose level.
Key findings from the Phase I assessment included:
- CAR-T Cell Expansion and Persistence: The median time for peak CAR-T cell expansion was observed at 14 days post-infusion, with median levels reaching 6.3 x 10^4 copies/µg. Encouragingly, CAR-T cell persistence was documented for up to six months in one patient, suggesting the potential for sustained therapeutic activity.
- Safety Profile and Dose-Limiting Toxicities: Within the critical first 28 days following infusion, no dose-limiting toxicities (DLTs) were identified, indicating an acceptable safety profile at the tested dose ranges.
- Cytokine Release Syndrome (CRS): A significant proportion of patients, 72.7%, experienced cytokine release syndrome. However, the severity was predominantly manageable, with Grade 1 CRS observed in 50% of patients and Grade 2 CRS in 21.7%. Importantly, no Grade 3 or higher CRS was reported. Haematological toxicities were also noted as manageable.
- Initial Efficacy Signals: The early efficacy data from the CONQUER trial demonstrated a promising three-month maximum objective response rate (ORR) of 81.8%. Of particular note, a combined complete response (CRc) rate of 54.5% was achieved. Crucially, all patients who responded to the therapy were confirmed to be minimal residual disease (MRD)-negative by flow cytometry, signifying a deep and potentially curative response.
However, the trial also highlighted a substantial and concerning challenge:
- Striking Incidence of Infections: A high incidence of severe infections was a significant finding, with 90.9% of patients encountering Grade 3 or higher infections. This included a substantial burden of viral reactivations, with Epstein-Barr virus (EBV) infections reported in 63.6% of patients and cytomegalovirus (CMV) infections in 45.5%.
- Infection-Related Mortality: Tragically, seven infection-related deaths occurred among patients who had not proceeded to consolidative HCT.
- Overall Survival: The reported overall survival within the trial was a median of 3.6 months.
It is imperative to acknowledge several important caveats in the interpretation of these initial findings. The researchers noted that an undisclosed number of patients opted to refuse allogeneic HCT. Furthermore, the outcomes were not stratified by specific patient subgroups or their prior treatment histories, which could potentially influence the observed results and lead to a more negative interpretation of the data than might be warranted.
Moving Forward: Refining the Approach for Improved Outcomes
Recognizing the significant potential alongside the identified challenges, the research team is actively pursuing further development of SL105. The recommended Phase II dose (RP2D) has been established at 2.0 x 10^6 CAR-T cells/kg. This higher dose will be administered to a larger cohort of patients, allowing for more robust evaluation of efficacy and safety.
Crucially, protocol modifications are being implemented to address the high incidence of non-relapse mortality, primarily driven by infections. A key change will be the earlier integration of HCT following CAR-T administration. This strategic shift aims to provide a more definitive treatment pathway and mitigate the risks associated with prolonged immune suppression and opportunistic infections that can arise after CAR-T therapy. The ultimate goal is to significantly reduce the incidence of non-relapse mortality and improve the long-term survival prospects for patients.
A Developing Landscape: Emerging Therapies for T-Cell Malignancies
The CONQUER trial’s findings are not an isolated development in the quest for effective T-cell CAR-T therapies. In November 2025, March Biosciences, a US-based company, presented interim results from its Phase II trial (NCT06534060) investigating its own nanobody-based autologous CD5 CAR-T construct, MB-105. This study builds upon the positive findings from a 2023 trial (NCT0308190).
The March Biosciences study was smaller in scale, evaluating only four patients over a 28-day period. Nevertheless, it reported a remarkable 100% objective response rate (ORR). The majority of adverse events observed were classified as Grade 1, and 50% of patients experienced CRS, again predominantly of manageable severity. Similar to the CONQUER trial, two cases of viral reactivation or infection were noted, but these were reported as Grade 2 or lower, suggesting a potentially more controlled infectious profile in this instance.
Despite these promising short-term efficacy and safety signals, GlobalData’s likelihood of approval (LoA) assessment for MB-105 currently projects a low 12% for its intended use in treating T-ALL. This cautious outlook underscores the industry’s anticipation of further data and potentially the need for demonstrated long-term survival benefits.
Implications and Future Directions: A Bridge to Curative Therapies?
The emergence of novel nanobody-based CD5 CAR-T therapies like SL105 and MB-105 represents a significant step forward in the treatment of T-ALL and PTCL. The ability to circumvent the fratricide mechanism, a persistent hurdle, is a testament to scientific innovation. The observed high response rates and achievement of MRD negativity in the CONQUER trial are particularly encouraging, suggesting these therapies could offer a powerful new avenue for patients with limited options.
However, the substantial incidence of severe infections and subsequent mortality in the CONQUER trial cannot be overstated. This highlights the critical need for comprehensive strategies to manage infectious complications and improve long-term survival. The proposed integration of earlier HCT in future SL105 trials is a crucial step in this direction.
At present, these novel CAR-T therapies appear most promising as potent "bridge" therapies. Their ability to induce deep remissions and achieve MRD negativity could effectively prepare patients for more definitive curative treatments, such as allogeneic HCT. While their potential as standalone, long-term curative therapies remains to be fully established, the ongoing research and development efforts, particularly those focused on mitigating infectious risks and improving overall survival, hold significant promise for transforming the treatment landscape for patients with these challenging T-cell malignancies. The coming years will undoubtedly be crucial in determining the ultimate role of these innovative CAR-T approaches in the fight against T-cell leukemias and lymphomas.
About the Author
